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Mesenchymal stem cells (MSCs) may cure life-threatening
acute GVHD, but long-term survival has been unsatisfactory.
The placenta protects the fetus from the mother’s immune
system, and placental tissues have been used for over 100
years in Africa to successfully treat burn injuries. Decidual
stromal cells (DSCs) are accessible without any invasive
procedure, with little or no need for ethical considerations,
as the placenta is normally discarded after delivery. We
isolate, culture, expand, and store DSCs from term placentas.
They have fundamental differences to MSCs. DSCs do not
differentiate as well to bone or cartilage. DSCs need cell-to-
cell contact to be immunosuppressive and to induce FoxP3
regulatory T-cells. Blocking of the activity of IDO, prosta-
glandin E2, PD-L1, and interferon impairs the immunosup-
pressive capacity of DSCs inMLC. Human DSCs inhibit MLC in
mice. MCSs and DSCs induce xenoreactivity.
In culture, DSCs can be expanded appreciably, and from
one placenta we can obtain enough cells to treat more than
20 patients.With early treatment (withinmedian six days) of
steroid refractory acute GVHD, one-year survival was 73%d
as opposed to 6% in retrospective controls not treated with
stromal cells (p<0.001). A partial responsewas seen in two of
three patients with severe chronic GVHD. Twelve patients
have been treated for hemorrhagic cystitis, and nowwe have
proceeded with a prospective double-blind randomized
study. A 33-year-old man developed acute respiratory
distress syndrome (ARDS) after septicemia and ASCT. He
required 15 L/min oxygen by mask. After infusion of 1  106
DSCs, oxygen saturation increased instantly from 92% to 98%;
requirement for oxygen decreased, and it was discontinued
after ﬁve days. Chest radiography improved and elevations in
cytokines/chemokines, G-CSF, IL-6, IL-8, MCP-1, and TNF-alfa
decreased. The patient is now alive and well eight months
after ASCT. We reversed paresis in the arms and legs
(respectively) of two patients with polyneuropathies. The
ﬁrst patient had recurrence of paresis and needed two
additional infusions of DSCs. The second patient has no
symptoms four months after infusion. Altogether, we have
treated 59 patients with 136 doses of DSCs and we have not
seen any acute side effects.
To conclude, DSCs are an effective therapy for acute and
chronic GVHD, hemorrhagic cystitis, ARDS, and neuropathy.
So far, we have not seen any side effects.
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Although autologous or donor-derived EBV-speciﬁc T cells
(EBVSTs) have remarkable clinical efﬁcacy for Hodgkin and
non-Hodgkin lymphoma, the lengthy manufacturing process
and anergy of patient tumor-speciﬁc T cells reduce the
feasibility of widespread use. An alternative approach is
establishment of a pre-made third party bank that can pro-
vide access to VSTs for almost any patient. We previously
evaluated multivirus-speciﬁc third-party T cells for re-
fractory viral infections after HSCT. Of 50 recipients, 74%
responded, even when T cells were HLA-matched at only a
single allele. Although established banks consist primarily of
donors from national marrow registries or family members
according to HLA genotype, there aremany limitations to this
approach, including the generation of lines with limited
speciﬁcity for the targeted antigens. To circumvent these
drawbacks, we have developed a strategic approach to
generating third-party lines for treatment of EBV+ lym-
phoma. Our bank has been generated from blood-bank
eligible donors, initially chosen based on racial diversity thus
predicted to have HLA haplotypes representative of our
diverse patient population. Donors were subsequently
screened for speciﬁcity to the EBV Type 2 latency antigens
(LMP1/2, EBNA1, and BARF1) with IFN-g Elispot assays using
overlapping peptide libraries (pepmixes) spanning each an-
tigen. The EBVSTs exhibited signiﬁcant speciﬁcity (with
>50% of donors recognizing 3 of the 4 antigens) and cyto-
toxicity to both pepmix-pulsed autologous activated T cells
(ATCs) and HLA-matched EBV-lymphoblastoid cell lines
(LCLs) that naturally express viral antigens. To ensure that
the best EBVST line is chosen for each recipient, it is impor-
tant to ensure antigen-speciﬁc activity restricted by the al-
leles shared between donor and recipient. To characterize
HLA restrictionwe use peptides or pepmix-pulsed PHA blasts
or LCLs that are HLA matched at a single class I or II allele as
target cells in cytotoxicity assays. We then constructed a
database in which the HLA restriction of the antigen speci-
ﬁcity of each T cell line is listed. Based on data from our third
party trivirus-speciﬁc T cell study, we expect that our pro-
jected bank of 30 highly characterized EBVSTs will cover
>95% of referred patients (with matching at  2 class I and/
or class II alleles) since our screening strategy ensures that a
wide range of HLA haplotypes is covered. Additionally, given
the signiﬁcantly increased virus speciﬁcity of our highly
characterized donors, we expect to see signiﬁcant anti-tu-
mor activity. This study will therefore allow us to determine
whether third-party T cells can be effective outside the HSCT
setting in patients who are not immunocompromised.176
Treatment of Secondary Graft Failure after Hematopoietic
Stem Cell Transplantation with Alpha/Beta T-Cell
Depleted Grafts As Booster Infusions
Emelie Rådestad 1,2, Helena Wikell 1,3, Mats Engström1,2,
Emma Watz 1,3, Berit Sundberg 1,2, Sarah Thunberg 3,
Mehmet Uzunel 3, Jonas Mattsson 1,2, Michael Uhlin 1,2,3.
1Department of Oncology-Pathology, Karolinska Institutet,
Stockholm, Sweden; 2 Center for Allogeneic Stem Cell
Transplantation, Karolinska University Hospital, Stockholm,
Sweden; 3 Department of Clinical Immunology and Transfusion
Medicine, Karolinska University Hospital, Stockholm, Sweden
